We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cyproheptadine and Chlorpromazine Effects on Spasticity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01509885
Recruitment Status : Completed
First Posted : January 13, 2012
Last Update Posted : November 20, 2012
Information provided by (Responsible Party):
University of Alberta

Brief Summary:
The main goal of this research is to understand the neuronal mechanisms that mediate the development of spasticity and motor dysfunction after spinal cord injury. The investigators examine how neurons and neuronal circuits in an injured nervous system adapt to produce the uncontrolled and unwanted muscle contractions that affect the majority (80%) of patients with spinal cord injury. One of the neurons that the investigators study is the motoneuron that excites the muscles of the limbs to produce movement. Previously, the investigators have shown that after spinal cord injury, the excessive and uncontrolled activity of motoneurons during muscle spasms is mediated, in large part, by the activation of calcium currents in the human motoneuron. In human patients the investigators have used recordings from single muscle fibres to estimate the contribution of these calcium currents in activating the motoneuron during muscle spasms. In this proposal, the investigators study why motoneurons recover these calcium currents and self-sustained activity after chronic spinal cord injury. Because the calcium currents require the presence of the monoamine serotonin (5HT) to activate, and this monoamine is greatly reduced after injury, the investigators examine if the calcium currents recover because the 5HT receptors become spontaneously active without the need for 5HT to bind to the receptor, which the investigators hypothesize to be one of the causes of spasticity after spinal cord injury. This research will pave the way to develop new pharmacological and rehabilitative therapies to both control spasticity after spinal cord injury and augment residual motor movements.

Condition or disease
Spinal Cord Injuries Muscle Spasticity

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Official Title: Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury
Study Start Date : July 2010
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

Complete Spinal Cord Injured Subjects
Patients with no motor scores in their legs and suffering a complete spinal cord injury.
Incomplete Spinal Cord Injured Subjects
Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.

Primary Outcome Measures :
  1. Cutaneomuscular Reflex Responses [ Time Frame: Change after drug intake at baseline, 30minutes, 60minutes, 90minutes and 120minutes ]
    Tibialis anterior reflex responses evoked by stimulation of the medial arch of the foot will be measured before and after drug administration.

  2. Paired motor unit recordings [ Time Frame: Change at baseline and 30, 60, 90 and 120min after drug intake ]
    We obtain paired motor unit recordings to determine changes in neuronal excitability after drug intake in incomplete spinal-cord injured subjects only.

Secondary Outcome Measures :
  1. Blood pressure and Heart rate [ Time Frame: Change at baseline and 30, 60, 90, 120 minutes after drug intake ]
    We measure blood pressure and heart rate to determine the safety of the drug during the experiment and whether we can continue safely.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   17 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Spinal Cord Injury Patients

Inclusion Criteria:

Patients must have suffered a trauma to the spinal cord at least 6 months ago or longer. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score, as assessed by a physical therapist, greater than 1.

Exclusion Criteria:

  • If patients have damage to the nervous system other than to the spinal cord
  • Pregnant women
  • Elderly Patients and debilitated patients
  • Alcoholic Patients
  • Patients with:

    • Known or suspected allergy to the medication or its ingredients
    • Cardiovascular disease
    • Hypotension
    • Coronary artery disease
    • Reduced liver or kidney function
    • Comatose or depressed states due to CNS depressants
    • Blood dyscrasias
    • Bone marrow depression
    • History of seizures
    • Respiratory problems
    • Hypocalcemia
    • Monoamine oxidase inhibitor therapy
    • Angle-closure glaucoma
    • Stenosing peptic ulcer
    • Symptomatic prostatic hypertrophy
    • Bladder neck obstruction
    • Pyloroduodenal obstruction
    • History of bronchial asthma
    • Increased intraocular pressure
    • Hyperthyroidism
    • Cardiovascular disease
    • Hypertension
  • Patients taking:

    • Amphetamines
    • Antihistamines-second generation
    • Anticonvulsants
    • Anticholinergics
    • CNS depressants
    • Antidepressants
    • Hypotensive agents
    • Levodopa
    • Lithium

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01509885

Layout table for location information
Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G2R3
Sponsors and Collaborators
University of Alberta
Layout table for investigator information
Principal Investigator: Monica A Gorassini, PhD University of Alberta
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: University of Alberta
ClinicalTrials.gov Identifier: NCT01509885    
Other Study ID Numbers: Pro00020682
First Posted: January 13, 2012    Key Record Dates
Last Update Posted: November 20, 2012
Last Verified: November 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations